biOasis preclinical data

In HER2-positive breast cancer cell lines, BT2111 displayed significantly improved anticancer activity vs. trastuzumab alone. BT2111 is trastuzumab conjugated to biOasis' Transcend carrier protein. Transcend is a p97 carrier protein that transports therapeutics across the blood brain barrier (BBB). The company plans to start Phase I testing of BT2111 by year end. ...